St. Jude Medical (NYSE:STJ) landed CE Mark approval in the European Union for a trio of neurostimulation devices in treatment of primary and secondary dystonia, the 1st such CE Mark of its kind.
The newly approved Brio, Libra and LibraXP deep brain stimulation systems are the 1st CE Marked devices to treat both primary and secondary dystonia with deep brain stimulation, in which mild electrical pulses are send to targeted ares of the brain.
"This CE Mark is the 1st approval by a regulatory agency for the use of deep brain stimulation therapy to manage the symptoms of both primary and secondary dystonia, broadening the treatment options for patients in Europe whose lives are impacted by this disabling disease," St. Jude medical implantable electronic systems president Dr. Eric Fain said in prepared remarks. "This approval represents a significant milestone for St. Jude Medical as we continue to develop therapies to treat a broad range of neurological conditions."
Dystonia is a neurological condition marked by involuntary muscle contractions and spasms. St. Jude’s implantable devices deliver electrical pulses to either the subthalamic nucleus or the globus pallidus interna, areas of the brain involved with controlling movement.
